Omega-3 LCPUFA Supplementation; Activating a Protective Cardiovascular Response in Patients with Advanced Chronic Kidney Disease
This article at a glance
- In this report the authors present the changes in plasma levels of EPA- and DHA-derived lipid mediators in response to an eight-week supplementation with omega-3 LCPUFA in patients with advanced chronic kidney disease.
- Importantly the study shows that even in an advanced disease state the body remains capable of mounting a protective tissue response with an increased level of resolvin D1.
- This is one of the first studies showing lipid mediator formation in response to omega-3 LCPUFA supplementation in a randomized placebo-controlled double-blinded trial of a patient group with a defined disease.
- This study provides a new basis to start addressing improving the maladaptive cardiovascular changes and renal fibrotic state that characterizes advanced CKD.